Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Molecular Insight Pharmaceuticals has reported positive results from two preclinical studies that demonstrated the potential of indium-111-edotreotide as an imaging tool to predict Onalta absorption in body tissues and to aid in determining appropriate patient dose.
Subscribe to our email newsletter
The studies evaluated the tissue distribution and pharmacokinetics of indium-111-edotreotide in two animal models. One study included in vitro studies and evaluated another potential imaging surrogate, indium-111-pentetreotide (Octreotide).
Tissue distribution comparisons of the compounds in all organs were virtually identical except in the kidneys, where indium-111-edotreotide predictably and consistently overestimated the Onalta absorbed radiation dose.
Onalta is in development as a targeted radiotherapeutic for the treatment of carcinoid and pancreatic neuroendocrine tumors. The in vitro and in vivo studies are part of Molecular Insight’s clinical program to support a planned US dosimetry trial later in 2008.
John Babich, president and chief scientific officer of Molecular Insight, said: “These studies compared the tissue distribution and pharmacokinetic profiles of induim-111- and yttruim-90- labeled edotreotide in order to determine whether indium-111-edotreotide is a suitable imaging predictor for the organ distribution of yttrium-90-edotreotide, the radiotherapeutic peptide.”